120 related articles for article (PubMed ID: 1762644)
1. Cost-effectiveness of drug abuse treatment: relevant issues and alternative longitudinal modeling approaches.
Hser YI; Anglin MD
NIDA Res Monogr; 1991; 113():67-93. PubMed ID: 1762644
[No Abstract] [Full Text] [Related]
2. Evaluating the cost-effectiveness of drug abuse treatment services.
Apsler R
NIDA Res Monogr; 1991; 113():57-66. PubMed ID: 1762643
[No Abstract] [Full Text] [Related]
3. Forecasting the cost of drug abuse treatment coverage in private health insurance.
McGuire TG; Shatkin BF
NIDA Res Monogr; 1991; 113():175-89. PubMed ID: 1762639
[No Abstract] [Full Text] [Related]
4. New perspectives on the benefit-cost and cost-effectiveness of drug abuse treatment.
Hubbard RL; French MT
NIDA Res Monogr; 1991; 113():94-113. PubMed ID: 1762645
[No Abstract] [Full Text] [Related]
5. Application of case management to drug abuse treatment: overview of models and research issues.
Ridgely MS; Willenbring ML
NIDA Res Monogr; 1992; 127():12-33. PubMed ID: 1435992
[No Abstract] [Full Text] [Related]
6. Financing treatment for substance abuse.
Pauly MV
NIDA Res Monogr; 1991; 113():165-74. PubMed ID: 1762638
[No Abstract] [Full Text] [Related]
7. The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data.
Harwood HJ; Hubbard RL; Collins JJ; Rachal JV
NIDA Res Monogr; 1988; 86():209-35. PubMed ID: 3140032
[No Abstract] [Full Text] [Related]
8. Integrating qualitative and quantitative components in evaluation of case management.
Willenbring ML
NIDA Res Monogr; 1992; 127():223-50. PubMed ID: 1435997
[No Abstract] [Full Text] [Related]
9. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
Woodward AM; Raskin IE; Blacklow B
Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
[TBL] [Abstract][Full Text] [Related]
10. Organizational and client determinants of cost in outpatient substance abuse treatment.
Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
[TBL] [Abstract][Full Text] [Related]
11. Some design, measurement, and analysis pitfalls in drug abuse prevention research and how to avoid them: let your model be your guide.
Collins LM
NIDA Res Monogr; 1994; 139():95-114. PubMed ID: 8742553
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
[TBL] [Abstract][Full Text] [Related]
13. Measuring youth outcomes from alcohol and drug treatment.
Brown SA
Addiction; 2004 Nov; 99 Suppl 2():38-46. PubMed ID: 15488104
[TBL] [Abstract][Full Text] [Related]
14. Willingness-to-pay (WTP): the new-old kid on the economic evaluation block.
Gafni A
Can J Nurs Res; 2001 Jun; 33(1):59-64. PubMed ID: 11928155
[No Abstract] [Full Text] [Related]
15. A research agenda for economic evaluation of substance abuse services.
French MT; Drummond M
J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
[TBL] [Abstract][Full Text] [Related]
16. Challenges in measuring patient outcomes.
Strickland OL
Nurs Clin North Am; 1997 Sep; 32(3):495-512. PubMed ID: 9254635
[TBL] [Abstract][Full Text] [Related]
17. An analysis of substance abuse patterns, medical expenses and effectiveness of treatment in the workplace.
Yu J; Chen PJ; Harshman EJ; McCarthy EG
Empl Benefits J; 1991 Sep; 16(3):26-30. PubMed ID: 10170845
[TBL] [Abstract][Full Text] [Related]
18. Phase III: research designs for future studies.
Splett PL
J Am Diet Assoc; 1991 Nov; Suppl():S43-50. PubMed ID: 1939969
[No Abstract] [Full Text] [Related]
19. Are there distinctive trajectory groups in substance abuse remission over 10 years? An application of the group-based modeling approach.
Xie H; Drake R; McHugo G
Adm Policy Ment Health; 2006 Jul; 33(4):423-32. PubMed ID: 16691463
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
Yeom HS; Shepard DS
J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
